Development
ADMA Biologics, Inc.
ADMA
$18.54
-$0.42-2.22%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 57.15% | 67.54% | 44.91% | 39.08% | 8.02% |
| Total Depreciation and Amortization | 17.14% | 21.89% | 26.78% | 29.02% | 29.43% |
| Total Amortization of Deferred Charges | 7.99% | -0.90% | 38.28% | 13.08% | 26.59% |
| Total Other Non-Cash Items | 138.91% | -30.08% | -24.93% | -19.24% | 325.30% |
| Change in Net Operating Assets | 44.64% | 64.28% | 36.52% | 57.81% | 64.62% |
| Cash from Operations | 114.79% | 81.10% | 51.65% | 54.15% | 47.04% |
| Capital Expenditure | 65.70% | 47.09% | 24.92% | 5.58% | -2.96% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 64.19% | 47.09% | 24.92% | 5.58% | -2.96% |
| Total Debt Issued | -11.04% | -100.00% | -100.00% | -100.00% | -- |
| Total Debt Repaid | -58.54% | 99.98% | 99.97% | 99.96% | -291,549.85% |
| Issuance of Common Stock | -98.30% | 22.45% | 5.24% | -18.19% | -46.49% |
| Repurchase of Common Stock | 51.19% | -277.99% | -733.40% | -3,580.36% | -4,606.17% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -215.21% | 100.00% | 90.76% | 90.76% | -- |
| Cash from Financing | -135.82% | -37.21% | -43.57% | -51.82% | -10.08% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -199.26% | 7,823.15% | 0.92% | -103.98% | 833.28% |